|
90
|
The SFDA Advises to Avoid Using NSAIDs in Pregnancy at 20 Weeks or Later
|
|
Warning
|
|
|
86
|
Safety Signal of Indapamide and the Risk of Rhabdomyolysis
|
|
Signal
|
|
|
85
|
Safety Signal of Theophylline and the Risk of Encephalopathy
|
|
Signal
|
|
|
84
|
Safety Signal of Amitriptyline and the Risk of Drug Reaction with Eosinophilia and Systemic Symptoms
|
|
Signal
|
|
|
83
|
Safety Signal of Nivolumab and the Risk of Hypoparathyroidism
|
|
Signal
|
|
|
82
|
Potential Risk of Tumor Lysis Syndrome Associated with the Use Pazopanib
|
|
Precautions
|
|
|
80
|
Safety Signal of Hypokalemia associated with the use of Ceftriaxone
|
|
Signal
|
|
|
79
|
Safety Signal of Molluscum Contagiosum associated with the use of Fingolimod
|
|
Signal
|
|
|
78
|
Safety Signal of Rhabdomyolysis associated with the use of Pembrolizumab
|
|
Signal
|
|
|
75
|
Safety Signal of Skin Cancer associated with the use of Methotrexate
|
|
Signal
|
|
